跳轉至內容
Merck
全部照片(2)

重要文件

B3170

Sigma-Aldrich

Monoclonal Anti-Bcl-2 antibody produced in mouse

clone Bcl-2-100, ascites fluid

同義詞:

Anti-BCL-2

登入查看組織和合約定價


About This Item

MDL號碼:
分類程式碼代碼:
12352203
NACRES:
NA.41
暫時無法取得訂價和供貨情況

生物源

mouse

共軛

unconjugated

抗體表格

ascites fluid

抗體產品種類

primary antibodies

無性繁殖

Bcl-2-100, monoclonal

分子量

antigen 26 kDa

包含

15 mM sodium azide

物種活性

human

應無反應活性

mouse

技術

electron microscopy: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:1,000 using human HeLa cell extract

同型

IgG1

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

基因資訊

human ... BCL2(596)

一般說明

BCL2 (B-cell lymphoma 2) consists of pro- and antiapoptotic functions. It belongs to BCL2 family of proteins. It is mapped to human chromosome 18q21.3.

免疫原

synthetic peptide corresponding to residues 41-54 of the Bcl-2 protein, conjugated to thyroglobulin.

應用

Anti-BCL2 (Ab-56) antibody has been used in western blotting and immunocytochemistry.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Monoclonal Anti-Bcl-2 antibody produced in mouse is suitable for western blotting at a concentration of 1:1,000 by using human HeLa cell extract. It is also suitable for immunohistochemistry by using formalin-fixed, paraffin-embedded tissue sections or frozen sections. Further, the antibody may be used for the localization of Bcl-2, by implementing numerous assays like- microarray, electron microscopy and immunoprecipitation.

生化/生理作用

BCL2 (B-cell lymphoma 2) plays an important role in the growth and progression of cancer. Overexpression of BCL2 (B-cell lymphoma 2) results in poor clinical predictions in diffuse large B-cell lymphoma (DLBCL). Bcl2 is highly essential for the survival of kidney and melanocyte stem cells and mature lymphocytes. It may control Bcl2 multiple initiator caspases.
Protooncogene BCL2 encodes a 26 kD integral outer mitochondrial membrane protein expressed in sub-cellular components such as the mitochondria and nucleus. While mitochondrial BCL2 inhibits apoptosis, BCL2 present in the nucleus may activate cell death. It may also regulate autophagy during starvation. Additionally, BCL2 facilitates the survival of central and peripheral neurons grown in culture in the absence of neurotrophic factors.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

BCL2 genotypes and prostate cancer survival
Renner W, et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [Et Al], 193(6), 466-471 (2017)
The Bcl2 family: regulators of the cellular life-or-death switch
Cory S and Adams JM
Nature Reviews. Cancer, 2(9), 647-656 (2002)
Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway
Bao H, et al.
Oncology Letters, 14(3), 2831-2837 (2017)
Raquel Vinhas et al.
Molecular therapy. Nucleic acids, 7, 408-416 (2017-06-19)
Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation
Tsuyama N, et al.
Blood, 130(4), 489-500 (2017)

文章

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務